Articles related to ATRIAL FIBRILLATION (AFIB)

The SAGE-AF study provides valuable insights into the cost-reducing behaviors among older adults with atrial fibrillation, highlighting the need for targeted interventions, especially for those with cognitive impairments. Explore the study to understand how these behaviors are shaping medication management in this vulnerable population.

Accelerate your understanding of thrombotic disease treatment developments; delve into the Fast Track designation of milvexian, a promising oral factor XIa inhibitor.

Navigating the Interplay of Eliquis and Dietary Habits As physicians, understanding the nuances of apixaban (Eliquis) and its interaction with diet is crucial for optimal patient care. While taking Eliquis, there are no specific foods to avoid, but people with cardiovascular issues should steer clear of coffee and foods heavy in fat.

Long-term continuous monitoring for atrial fibrillation in older patients yielded an incidental diagnosis of sinus node dysfunction or atrioventricular block with bradycardia in 21% of patients over the age of 70. But the finding was not associated with any increased risk of syncope or sudden death.

Medical records of more than half a million individuals in the EU, UK, and US were evaluated. Apixaban was the most frequently prescribed direct oral anticoagulant (DOAC) for AFib. It was also associated with a lower incidence of GI bleed vs. the other DOACs.

According to new information revealed in a study of the AHA’s COVID-19 Cardiovascular Disease Registry, new onset AFib occurs in 5% of patients hospitalized with COVID-19. Patients who developed new-onset AFib experienced longer hospital stays and approximately 45% died during their hospitalization. Atrial fibrillation can directly increase the risk of stroke and prolong hospitalization. It is also an indirect marker of the insult that the heart is experiencing when patients are infected with COVID-19.